Alpelisib: observed
16 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesNot yet recruitingNCT07767877Report a problem
- A Post Marketing Surveillance on Piqray in KoreaRecruitingNCT05293470Report a problem
- Managed Access Programs for BYL719, AlpelisibAvailableNCT04085653Report a problem
- Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received AlpelisibCompletedNCT04285723Results postedReport a problem
- A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or AlpelisibCompletedNCT06705504Report a problem
- Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating AlpelisibCompletedNCT06083038Report a problem
- Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast CancerCompletedNCT05982886Report a problem
- A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of TherapyCompletedNCT05853432Report a problem
- Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational StudyCompletedNCT05294289Report a problem
- Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using AlpelisibCompletedNCT05073120Report a problem
- Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-worldCompletedNCT05022342Report a problem
- A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world SettingTerminatedNCT04967248Report a problem
- A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in RussiaCompletedNCT04943497Report a problem
- Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.Status unknownNCT04852081Report a problem
- Compassionate Use of BYL 719 AlpelisibNo longer availableNCT03941782Report a problem
- Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast CancerNo longer availableNCT03706573Report a problem